Quantification of superparamagnetic iron oxide-mediated signal intensity change in patients with liver cirrhosis using T2 and T2* mapping: A preliminary report

Journal of Magnetic Resonance Imaging

Volumn 31, Issue 6, 2010, Pages 1379-1386

  Chung, Yong Eun ^a   Park, Mi Suk ^a   Kim, Myoung Soo ^a   Kim, Eunju ^b   Park, Jaeseok ^a   Song, Ho Taek ^a   Choi, Jin Young ^a   Kim, Myeong Jin ^a   Kim, Ki Whang ^a  

^a Yonsei University College of Medicine   (South Korea)

^b PHILIPS HEALTHCARE   (United States)

Author keywords

Contrast agent; Liver cirrhosis; Magnetic resonance imaging; Relaxometry; Superparamagnetic iron oxide

Indexed keywords

FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CONTRAST ENHANCEMENT; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; LIVER CIRRHOSIS; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; STATISTICAL ANALYSIS; VOLUNTEER; AREA UNDER THE CURVE; BIOPSY; IMAGE PROCESSING; LIVER; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; REPRODUCIBILITY;

ADULT; AGED; AREA UNDER CURVE; BIOPSY; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 77952825647     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22184     Document Type: Article

References (38)

1. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-1457. (Pubitemid 37466971)
2. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986;2:165-173. (Pubitemid 16125908)
3. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;1:523-525. (Pubitemid 16138427)
4. Thuluvath PJ, Krok KL. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Am J Gastroenterol 2005;100:1981-1983.
5. Han KH, Yoon KT. New diagnostic method for liver fibrosis and cirrhosis. Intervirology 2008;51(Suppl 1):11-16. (Pubitemid 351821837)
6. Taouli B, Chouli M, Martin AJ, Qayyum A, Coakley FV, Vilgrain V. Chronic hepatitis: role of diffusion-weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. J Magn Reson Imaging 2008;28:89-95. (Pubitemid 351956470)
7. Venkatesh SK, Yin M, Glockner JF, et al. MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol 2008;190:1534-1540. (Pubitemid 351798532)
8. Carrion JA, Navasa M, Forns X. MR elastography to assess liver fibrosis. Radiology 2008;247:591;
9. author reply, 591-592.
10. Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB. MR contrast agents for liver imaging: what, when, how. Radiographics 2006;26:1621-1636.
11. Oswald P, Clement O, Chambon C, Schouman-Claeys E, Frija G. Liver positive enhancement after injection of superparamagnetic nanoparticles: respective role of circulating and uptaken particles. Magn Reson Imaging 1997;15:1025-1031. (Pubitemid 27451311)
12. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR Am J Roentgenol 1990;155:943-950.
13. Tanimoto A, Yuasa Y, Shinmoto H, et al. Superparamagnetic iron oxide-mediated hepatic signal intensity change in patients with and without cirrhosis: pulse sequence effects and Kupffer cell function. Radiology 2002;222:661-666. (Pubitemid 34215210)
14. Hundt W, Petsch R, Helmberger T, Reiser M. Signal changes in liver and spleen after Endorem administration in patients with and without liver cirrhosis. Eur Radiol 2000;10:409-416. (Pubitemid 30145750)
15. Yamashita Y, Yamamoto H, Hirai A, Yoshimatsu S, Baba Y, Takahashi M. MR imaging enhancement with superparamagnetic iron oxide in chronic liver disease: influence of liver dysfunction and parenchymal pathology. Abdom Imaging 1996;21:318-323. (Pubitemid 26230767)
16. Elizondo G, Weissleder R, Stark DD, et al. Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 1990;174:797-801. (Pubitemid 20089674)
17. Kato N, Ihara S, Tsujimoto T, Miyazawa T. Effect of resovist on rats with different severities of liver cirrhosis. Invest Radiol 2002;37:292-298. (Pubitemid 34461675)
18. von Falkenhausen M, Meyer C, Lutterbey G, et al. Intra-individual comparison of image contrast in SPIO-enhanced liver MRI at 1.5T and 3.0T. Eur Radiol 2007;17:1256-1261. (Pubitemid 46691955)
19. Hamm B, Staks T, Taupitz M, et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J Magn Reson Imaging 1994;4:659-668.
20. Dahnke H, Schaeffter T. Limits of detection of SPIO at 3.0 T using T2 relaxometry. Magn Reson Med 2005;53:1202-1206. (Pubitemid 40627800)
21. Kuhlpeter R, Dahnke H, Matuszewski L, et al. R2 and R2* mapping for sensing cell-bound superparamagnetic nanoparticles: in vitro and murine in vivo testing. Radiology 2007;245:449-457.
22. Tanimoto A, Oshio K, Suematsu M, Pouliquen D, Stark DD. Relaxation effects of clustered particles. J Magn Reson Imaging 2001;14:72-77.
23. Child CG. The liver and portal hypertension. Philadelphia: Saunders; 1964. xiii, 231 p.
24. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
25. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
26. Garrison RN, Cryer HM, Howard DA, Polk HC Jr. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg 1984;199:648-655.
27. Bowen CV, Zhang X, Saab G, Gareau PJ, Rutt BK. Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells. Magn Reson Med 2002;48:52-61. (Pubitemid 34721587)
28. Zhang J, Krinsky GA. Iron-containing nodules of cirrhosis. NMR Biomed 2004;17:459-464.
29. Hezode C, Cazeneuve C, Coue O, et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999;31:979-984.
30. Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A. Hemosiderin deposition in portal endothelial cells: a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C. Hum Pathol 1995;26:1080-1085.
31. Girometti R, Furlan A, Bazzocchi M, et al. Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients. Radiol Med 2007;112:394-408.
32. Taouli B, Tolia AJ, Losada M, et al. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol 2007;189:799-806. (Pubitemid 47479760)
33. Qayyum A. Diffusion-weighted imaging in the abdomen and pelvis: concepts and applications. Radiographics 2009;29:1797-1810.
34. Luciani A, Vignaud A, Cavet M, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging - pilot study. Radiology 2008;249:891-899.
35. Huwart L, Sempoux C, Salameh N, et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 2007;245:458-466. (Pubitemid 47612527)
36. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54. (Pubitemid 40066382)
37. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;3:8.
38. Bourliere M, Penaranda G, Renou C, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006;13:659-670.